Differential effects of leptin in regulation of tissue glucose utilization in vivo.
We have recently shown that leptin enhances systemic insulin sensitivity and whole body glucose utilization in the rat. This study examines our hypothesis that leptin has differential effects in regulating glucose utilization among the tissues, i.e. stimulating glucose utilization in brown adipose tissue (BAT) and skeletal muscle but suppressing glucose utilization in white adipose tissue (WAT) in normal male rats (275-350 g BW). The rats were treated with s.c. infusion of recombinant murine leptin (4 mg/kg x day) or vehicle (V) with Alzet osmotic pumps or with vehicle and pair-feeding (PF) for 7 days. Leptin significantly decreased food intake (leptin, 11.5 +/- 0.4 g/day; V, 16.8 +/- 1.5 g/day; P < 0.05) and body weight (maximum change, 5.0 +/- 0.2%; P < 0.05 vs. V) and lowered plasma triglyceride, insulin, and glucose levels, but raised beta-hydroxybutyrate levels. Glucose utilization by individual tissues was determined with an i.v. bolus of [1-(14)C]2-deoxyglucose (2-DG) after a 90-min hyperinsulinemic (2 mU/kg x min) euglycemic clamp. With leptin treatment, the 2-DG-determined glucose utilization in interscapular BAT was almost 3-fold that in V-treated rats and 70% greater than that in PF rats. In contrast, in the epididymal WAT, glucose utilization was reduced by leptin treatment to only 34% that in V-treated rats and 45% that in PF rats. Leptin increased 2-DG uptake by extensor digitorum longus muscle and soleus muscle compared with that in the V and PF groups. With leptin treatment, the GLUT4 glucose transporter mRNA and protein levels were increased in BAT, but decreased in WAT (both P < 0.05). There was no significant change in GLUT4 mRNA and protein expression in extensor digitorum longus muscle and soleus muscle. Oxygen consumption was significantly increased (32.1 +/- 7.4%) in BAT (139.0 +/- 8.2 nmole O2/30 min x 10(6) cells) of leptin-treated rats vs. that in V control rats (105.3 +/- 6.7 nmole O2/30 min x 10(6) cells). In conclusion, leptin has differential, tissue-specific effects on glucose and oxygen utilization, which contribute to the reduction in whole body adiposity by enhancing energy consumption in BAT and muscle while attenuating energy storage in WAT.
Wang
J L
JL
Department of Pharmacology, Amgen, Inc., Thousand Oaks, California 91320, USA.
Chinookoswong
N
N
Scully
S
S
Qi
M
M
Shi
Z Q
ZQ
D020155:3-Hydroxybutyric Acid / Q000097:blood; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004435:Eating / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D051275:Glucose Transporter Type 4; D006706:Homeostasis / Q000187:drug effects*; D007328:Insulin / Q000097:blood; D020738:Leptin; D008297:Male; D051379:Mice; D009004:Monosaccharide Transport Proteins / Q000235:genetics / Q000378:metabolism; D009124:Muscle Proteins; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D011506:Proteins / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D051275:Glucose Transporter Type 4; D007328:Insulin; D020738:Leptin; D009004:Monosaccharide Transport Proteins; D009124:Muscle Proteins; D011506:Proteins; D012333:RNA, Messenger; D011994:Recombinant Proteins; C495693:Slc2a4 protein, mouse; C495694:Slc2a4 protein, rat; D014280:Triglycerides; D005947:Glucose; D020155:3-Hydroxybutyric Acid